?hei=328&fmt=png-alpha)
SARS-CoV-2 may be difficult for clinicians to identify on symptoms alone. Many patients may be asymptomatic and if left undiagnosed, it may result in health complications or community spread.
With more than 6.9 million deaths and over 771 million cases1 of COVID-19 reported so far worldwide, effective tools are needed to deliver rapid results to identify symptomatic and asymptomatic individuals infected with SARS-CoV-2.
cobas® SARS-CoV-2 is the first real-time polymerase chain reaction (PCR) test that provides targeted identification within 20 minutes for both asymptomatic and symptomatic persons, enabling informed decisions at the point of care.
cobas® SARS-CoV-2:
The cobas® SARS-CoV-2 assay runs on the cobas® liat system. Choosing speed and accuracy, anywhere and anytime is the Roche Total Solution for all that you value. The total point-of-care solution that is simply quick, gives you the confidence of PCR accuracy, and puts you in control, now with conveniently remote results, automatic reporting and one-click updates.
| Positive Agreement** | Negative Agreement** | |
|---|---|---|
| Symptomatic individuals LOD: 1.2 x 10-2 TCID 50/mL |
96.1 % (95% CI: 89.0%-98.6%) |
96.8 % (95% CI: 92.6%-98.6%) |
| Asymptomatic individuals LOD: 1.2 x 10-2 TCID 50/mL |
100 % (95% CI: 84.5%-100%) |
98.9 % (95% CI: 96.2%-99.7%) |
Rapidly test, triage, and treat your patients with the accuracy, simplicity, and security needed at the point of care.
CE-IVD, FDA Emergency Use Authorization (EUA)
The cobas® liat system is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.
Access package inserts through your country’s Roche Diagnostics Website.
References
COBAS and LIAT are trademarks of Roche.
